Table 3 Adverse events reported in >3 patients overall
Adverse event* | Vandetanib 100 mg (n= 10) n(%) | Vandetanib 300 mg (n= 12) n(%) | Total (n= 22) n(%) |
|---|---|---|---|
Fatigue | 6 (60) | 7 (58) | 13 (59) |
Rash† | 2 (20) | 10 (83) | 11 (50) |
Diarrhea | 2 (20) | 7 (58) | 9 (41) |
Dry mouth | 2 (20) | 4 (33) | 6 (27) |
Nausea | 3 (30) | 3 (25) | 6 (27) |
Anorexia | 3 (30) | 2 (17) | 5 (23) |
Dysphonia | 1 (10) | 4 (33) | 5 (23) |
Abdominal pain | 1 (10) | 3 (25) | 4 (18) |
Acne | 0 | 4 (33) | 4 (18) |
Cough | 1 (10) | 3 (25) | 4 (18) |
Dizziness | 3 (30) | 1 (8) | 4 (18) |
Dry skin | 1 (10) | 3 (25) | 4 (18) |
Flatulence | 1 (10) | 3 (25) | 4 (18) |
Hypertension | 1 (10) | 3 (25) | 4 (18) |
Insomnia | 3 (30) | 1 (8) | 4 (18) |
Nasopharyngitis | 2 (20) | 2 (17) | 4 (18) |
Peripheral edema | 4 (40) | 0 | 4 (18) |
Sinus tachycardia | 1 (10) | 3 (25) | 4 (18) |
Weight decreased | 1 (10) | 3 (25) | 4 (18) |